A clinical study on the combination of topotecan and cisplatin in treatment of advanced non-small cell lung cancer
LIU Gang, YANG He ping,HU Jian lin,et al. ( Department of Pulmonology,Southwest Hospital,the Third Military Medical University,Chongqing 400038)
Objective To evaluvate the efficacy and toxicity of the combination of topotecan and cisplatin in treatment of patients with advanced non small cell lung cancer(NSCLC).Methods Forty six patients with locally advanced (stage III) or metastatic (stage IV) NSCLC were enrolled into the study. The patients received topotecan 1.0～1.2 mg/m2 on day 1 5, and cisplatin 60～80mg/m2 on day 6 of the 21 day cycle. Results An objective response was obtained in 50.0% of patients (23 partial responses), whereas 15 patients had stable disease and 8 patients were progressive. The response rate was 54.8% in patients with no prior chemotherapy, and the response rate of 40.0% was achieved in patients who had given prior treatment. No significant difference existed between the two groups ( P 0.05). The median duration of survival was 10 months, and 1 year survival rate was 32.6%. Toxicity was chiefly hematologic in the form of neutropenia. The major nonhematologic toxicity was nausea or vomiting and alopecia. Conclusion The combination of topotecan and cisplatin is a feasible ,well tolerated, and active scheme in treatment of advanced NSCLC.
【CateGory Index】： R734.2